ContraFect (CFRX) Issues Quarterly Earnings Results

ContraFect (NASDAQ:CFRX) posted its quarterly earnings results on Friday. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.26, MarketWatch Earnings reports.

NASDAQ CFRX opened at $0.51 on Friday. ContraFect has a 1 year low of $0.35 and a 1 year high of $2.93. The firm has a market cap of $40.82 million, a price-to-earnings ratio of -1.39 and a beta of -0.35.

A hedge fund recently raised its stake in ContraFect stock. Geode Capital Management LLC boosted its position in shares of ContraFect Corp (NASDAQ:CFRX) by 8.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 377,908 shares of the biotechnology company’s stock after acquiring an additional 29,009 shares during the quarter. Geode Capital Management LLC owned 0.48% of ContraFect worth $578,000 at the end of the most recent reporting period. 55.54% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “ContraFect (CFRX) Issues Quarterly Earnings Results” was posted by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://dakotafinancialnews.com/2019/05/12/contrafect-cfrx-issues-quarterly-earnings-results.html.



About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Read More: Fiduciary

Earnings History for ContraFect (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.